Combining PD-1/PD-L1 inhibitor and PARP inhibitor: a new perspective on the treatment of triple negative breast cancer

Ruilian Xie

Article ID: 1372
Vol 5, Issue 2.1, 2021

VIEWS - 41 (Abstract) 31 (PDF)

Abstract


Compared with other types of breast cancer, triple negative breast cancer has a poor survival prognosis due to its high aggressiveness and lack of effective therapeutic targets. Immune checkpoint (PD-1/PD-L1 and CTL-4) inhibitors have emerged as a breakthrough therapy in the treatment in various metastatic cancers. PARP inhibitors promote DNA damage in tumor cells, not only promoting immune initiation through a series of molecular mechanisms, but also leading to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. Therefore, the combination of the two inhibitors can improve the efficacy of tumor treatment. We reviewed the research progress of their combined use in triple negative breast cancer, and put forward relevant ideas for further development, hoping to find the best treatment mode of the combined use of the two.


Keywords


Immunotherapy; PARP Inhibitors; Combined Therapies; Triple Negative Breast Cancer

Full Text:

PDF


References


1. Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016; 7(17): 24269–24283.

2. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine 2015; 373(13): 1270–1271.

3. Zak KM, Kitel R, Przetocka S, et al. Structure of thecomplex of human programmed death1 PD-1 and its ligand PD-L1. Structure 2015; 23(12): 2341–2348.

4. Boussiotis VA. Moleclar and biochemical aspects of the PD-1checkpoint pathway. New England Journal of Medicine 2016; 375(18): 1767–1778.

5. Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chinese Journal of Cancer Research 2014; 26(1): 104–111.

6. Anwar M, Aslam HM, Anwar S. PARP inhibitors. Hereditary Cancer in Clinical Practice 2015; 13(1).

7. Vyas S, Chang P. New PARP targets for cancer therapy. Nature Reviews Cancer 2014; 14: 502–509.

8. Wang Y, Liu W, Ning Y, et al. Progress in the research of PARP inhibitors and their mechanisms of action. Chinese Journal of New Drugs 2018; 27(3): 306–313.

9. Haddad M, Rhinn H, Bloquel C, et al. Anti-inflammatory effects of PJ34, a poly (ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. British Journal of Pharmacology 2006; 149(1): 23–30.

10. Laudisi F, Sambucci M, Pioli C. Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator. Endocrine Metabolic & Immune Disorders Drug Targets 2011; 11(4): 326–333.

11. Aldinucci A, Gerlini G, Fossati S, et al. A key role for poly (ADP-ribose) polymerase-1 activity during human dendritic cell maturation. Journal of Immunology 2007; 179(1): 305–312.

12. Valdor R, Schreiber V, Saenz L, et al. Regulation of NFAT by poly (ADP-ribose) polymerase activity in T cells. Molecular Immunology 2008; 45(7): 1863–1871.

13. Davalli P, Marverti G, Lauriola A, et al. Targeting oxidatively induced DNA damage response in cancer: Opportunities for novel cancer therapies. Oxidative Medicine and Cellular Longevity 2018; 21(3): 1–21.

14. Césaire M, Tharit J, Candéias SM, et al. Combining PARP inhibition, radiation and immunotherapy: A possible strategy to improve the treatment of cancer. International Journal of Molecular Sciences 2018; 19(12): 3793.

15. Huang J, Wang L, Cong Z, et al. The PARP1 inhibitor BMN673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. Biochemical and Biophysical Research Communications 2015; 463(4): 551–556.

16. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. Journal of Immunology 2009; 182(8): 4499–4506.

17. Lanca T, Costa MF, Goncalves-Sousa N, et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. Journal of Immunology 2013; 190(12): 6673–6680.

18. Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 blockade synergizes therapeutically with PARP Inhibition in BRCA1-deficient ovarian cancer. Cancer Immunology Research 2015; 3(11): 1257–1268.

19. Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer associated immunosuppression. Chinese Journal of Cancer Research 2017; 23(14): 3711–3720.

20. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development. Journal of Clinical Oncology 2015; 33(12): 1397–1406.

21. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1blockade. Science 2017; 357(6349): 409–413.

22. Nebot-Bral L, Brandao D, Verlingue L, et al. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. European Journal of Cancer 2017; 84: 290–303.

23. Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165(1): 35–44.

24. Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Reports 2017; 19(6): 1189–1201.

25. Shao B, Li C, Lim S, et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. American Journal of Cancer Research2018; 8(9): 1837–1846.

26. Karzai F, Madan RA, Owens H, et al. A phase 2 study ofolaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. Journal of Clinical Oncology 2018; 36: 163.

27. Drew Y, Park YH, Hong SH, et al. Anopen-label, phase Ⅱ basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitiverelapsed (PSR) ovarian cancer (OC). Gynecologic Oncology 2018; 149: 246–247.

28. Vinayak S, Tolaney SM, Schwartzberg LS, et al. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. Journal of Clinical Oncology 2018; 36: 1011.

29. Konstantinopoulos PA, Waggoner SE, Vidal GA, et al. TOPACIO/Keynote-162 (NCT02657889): Aphase1/2 study of niraparib p pembrolizumab in patients (pts) with advancedtriple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. Journal of Clinical Oncology 2018; 36: 106.

30. Friedlander M, Meniawy T, Markman B, et al. A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. Journal of Clinical Oncology 2017; 35(15): 3013.

31. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine 2017; 377(6): 523–533.

32. Kaufman H, Schwartz LH, William WN, et al. Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. Journal of Clinical Oncology 2017; 35: e14557.




DOI: https://doi.org/10.24294/ti.v5.i2.1.1372

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Ruilian Xie

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.